Innovation drives the regeneration of fusion engine. Recently released the patent entrepreneurship project of Zhongguancun National Intellectual Property System Demonstration Park in 2022. Good news came again that Dongfang Baitai was selected successfully. Innovation is the main color and background of Dongfang Baitai in 2022. It is the key to open a bright future. We are ready to move forward. 

On March 15, Zhongguancun Intellectual Property Promotion Center released the "Publicity on the evaluation results of the patent entrepreneurship funding Project of the Zhongguancun National Intellectual Property System Demonstration Park in 2022".  The project "Patent achievement transformation of anti-VEGFR-2 monoclonal antibody for tumor therapy" was successfully selected by Dongfang Baitai. 

The patent Entrepreneurship Project of Zhongguancun National Intellectual Property System Demonstration Park in 2022 will be supported in the following directions: patent projects involving strategic emerging industries in Zhongguancun;  Patent projects combining production, university and research.  All along, Dongfang Baitai has always adhered to the "development of innovative results" and "transformation of intellectual property rights".  We focus on the first trial to build demand traction.  The successful selection shows that the country and the government highly praise Dongfang Baitai for adhering to the path of innovative development.  

Dongfang Baitai fully implements the patented technology of "anti-VEGFR-2 fully human monoclonal antibody".  This project involves JY025, an all-human monoclonal antibody independently developed by the company.  JY025 is a class of innovative therapeutic biologics targeting vascular endothelial cell growth factor receptor-2 (VEGFR-2).  It is used to treat tumors such as liver cancer and lung cancer.  The product has independent intellectual property rights. At the same time, the distribution of domestic and foreign patents and Chinese authorized invention patents won the 2021 China Patent Excellence Award. 

JY025 products are fully human monoclonal antibody products.  JY025 is highly specific and can be directly combined with VEGFR2. Compared with chemotherapy drugs with broad-spectrum killing effect, JY025 will provide efficient and high-quality antibody drug choice for patients at home and abroad.  It will promote our economy and the development of the antibody industry and the stability and harmony of society.  

After years of development, the technology and process innovation capability of Dongfang Baitai has been continuously improved.  The number of valid invention patents, patent stability and patent value have been continuously enhanced.  In the product indications, cover malignant tumors, diabetes, autoimmune diseases, eye diseases, asthma and many other high incidence diseases. The company has created a number of high value patent fist products.  
In the future, Dongfang Baitai will continue to make efforts to research and develop new products and strict quality control.  Through continuous innovation, the latest and most effective drugs are available to the majority of patients.  We are making steady progress towards realizing the vision of "safeguarding human life and health". 

As the developer and leader of innovative antibody drugs

Dongfang Baitai is committed to creating a healthy human life

By the end of March 2022

Dongfang Baitai has applied for 109 invention patents in total

49 domestic patents

60 foreign patents

Continuously innovate and make contributions to the field of biomedicine

Standing at a new starting point of "innovative development"

Dongfang Baitai will take the development of antibody industry as the general outline

High quality and sustainable development first

Focus on improving the level of refined management

Better benefit the needs of patients in China and the world

Continue to enable the future development of biomedicine